These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31330833)

  • 1.
    Marisi G; Petracci E; Raimondi F; Faloppi L; Foschi FG; Lauletta G; Iavarone M; Canale M; Valgiusti M; Neri LM; Ulivi P; Orsi G; Rovesti G; Vukotic R; Conti F; Cucchetti A; Ercolani G; Andrikou K; Cascinu S; Scartozzi M; Casadei-Gardini A
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31330833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of
    Casadei-Gardini A; Marisi G; Dadduzio V; Gramantieri L; Faloppi L; Ulivi P; Foschi FG; Tamburini E; Vivaldi C; Rizzato MD; Ielasi L; Canale M; Conti F; Rudnas B; Fornaro L; Silvestris N; Silletta M; Cardellino GG; Lonardi S; Fornari F; Orsi G; Rovesti G; Zagonel V; Cascinu S; Scartozzi M
    Clin Cancer Res; 2020 Sep; 26(17):4485-4493. PubMed ID: 32371540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.
    Azuma S; Uojima H; Chuma M; Shao X; Hidaka H; Nakazawa T; Kondo M; Numata K; Iwabuchi S; Kako M; Maeda S; Koizumi W; Atsuda K
    Sci Rep; 2020 Oct; 10(1):17054. PubMed ID: 33051476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
    Casadei Gardini A; Marisi G; Faloppi L; Scarpi E; Foschi FG; Iavarone M; Lauletta G; Corbelli J; Valgiusti M; Facchetti F; Della Corte C; Neri LM; Tamberi S; Cascinu S; Scartozzi M; Amadori D; Nanni O; Tenti E; Ulivi P; Frassineti GL
    Oncotarget; 2016 May; 7(19):27988-99. PubMed ID: 27058899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
    Gardini AC; Faloppi L; Aprile G; Brunetti O; Caparello C; Corbelli J; Chessa L; Bruno D; Ercolani G; Leonetti A; Stefano G; Farella N; Foschi FG; Lanzi A; Dadduzio V; Marisi G; Masi G; Negri FV; Pagan F; Santini D; Scarpi E; Silletta M; Silvestris N; Tamburini E; Tassinari D; Vivaldi C; Gentilucci UV; Zagonel V; Calvetti L; Cascinu S; Frassineti GL; Scartozzi M
    Tumori; 2018 Dec; 104(6):476-479. PubMed ID: 29739298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOS3 Gene rs1799983 and rs2070744 Polymorphisms in Patients with Unstable Angina.
    Pawlik A; Błaszczyk H; Rać M; Maciejewska-Skrendo A; Safranow K; Dziedziejko V
    J Vasc Res; 2020; 57(3):136-142. PubMed ID: 32224624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
    Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
    Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of prognostic germline polymorphisms in patients with advanced hepatocellular carcinoma.
    Herman M; Lok BH; Gallinger S; Dawson L; Kim R; Cheng D; Paton T; Bucur R; Patel D; Fazelzad R; Hueniken K; Liu G
    Transl Gastroenterol Hepatol; 2023; 8():32. PubMed ID: 38021355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
    Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
    BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
    Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
    Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of NOS3 gene polymorphisms with essential hypertension in Sudanese patients: a case control study.
    Gamil S; Erdmann J; Abdalrahman IB; Mohamed AO
    BMC Med Genet; 2017 Nov; 18(1):128. PubMed ID: 29132319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
    Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
    J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials.
    Chen BB; Lin ZZ; Shao YY; Hsu C; Hsu CH; Cheng AL; Liang PC; Shih TT
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction.
    Al-Rajabi R; Patel S; Ketchum NS; Jaime NA; Lu TW; Pollock BH; Mahalingam D
    J Gastrointest Oncol; 2015 Jun; 6(3):259-67. PubMed ID: 26029452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
    J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
    Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.